SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Intellia Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's drug development programs [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $50,000 in Intellia between July 30, 2024, and January 8, 2025, to discuss their legal options [1]. - There is an April 14, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Intellia [2]. - The complaint alleges that Intellia and its executives made false statements regarding the Phase 1/2 study of NTLA-3001, failing to disclose critical information about the program's viability [4]. Group 2: Company Developments and Financial Impact - On January 9, 2025, Intellia announced a strategic shift, focusing on drug candidates NTLA-2002 and nex-z, while discontinuing NTLA-3001, leading to a workforce reduction of approximately 27% [5]. - The company expects to incur around $8 million in charges in Q1 2025 due to this restructuring [5]. - Following the announcement, Intellia's stock price dropped by $1.82 per share, or 15.14%, closing at $10.20 per share on January 10, 2025 [6].